EU Commission extends authorisation of Mpox vaccine to adolescents
The EU Commission has extended the authorisation of the Imvanex vaccine to adolescents aged 12 to 17 years. Imvanex is the only Mpox vaccine currently authorised in the EU, together with an antiviral treatment (Tecovirimat SIGA). The authorisation follows a recommendation from the European Medicines Agency (EMA).